Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Previously submitted to: JMIR Bioinformatics and Biotechnology (no longer under consideration since Feb 01, 2024)

Date Submitted: May 8, 2023

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

Expression Status of ABCC1, an ABC Transporter, Helps to Monitor Response to Chemotherapy in COAD Patients

  • Samina Ejaz

ABSTRACT

Background:

Worldwide increasing incident of colorectal adenocarcinoma (COAD) and development of resistance against chemotherapeutic drugs is a big challenge in recent era for researcher and health professional.

Objective:

This study was aimed to identify new biomarkers for early diagnosis, treatment and to overcome drug resistant in COAD patient. ABC transporter genes are key player in the development of resistance against chemotherapeutic drugs. Therefore, we initiate a study to explore the role of ABCC1 transporter by analyzing its mutatome, expression variations, promoter methylation level, clinical outcome, and drug sensitivity analysis in COAD patients

Methods:

We use cBioPortal and UALCAN to retrieve data regarding ABCC1 expression and its promoter methylation. KM plotter was used to retrieve data to study impact on survival of patient, and CCLE GDSC toolkit database was used for analysis of effect of ABCC1 overexpression on tumor’s response to various drugs.

Results:

Mutatome analysis show that in COAD patient ABCC1 was 2.2% mutated and most of frequent noted mutations were missense that are thought to be involved in up-regulation of ABCC1 transporter expression and may cause drug resistance. Data analysis from UALCAN showed that ABBC1 expression was high in COAD patients with various clinicopathological features than normal controls. Kaplan Meier survival analysis of ABCC1 show that overexpression decrease overall survival rate of the COAD patients.

Conclusions:

Ultimately, the overexpression of ABCC1 was found decreasing the sensitivity of various important chemotherapeutic drugs in COAD patient via CCLE GDSC toolkit database analysis. By controlling overexpression of ABCC1, drug resistance can be overcome and effectiveness of various drugs can be increased in COAD patient


 Citation

Please cite as:

Ejaz S

Expression Status of ABCC1, an ABC Transporter, Helps to Monitor Response to Chemotherapy in COAD Patients

JMIR Preprints. 08/05/2023:48813

DOI: 10.2196/preprints.48813

URL: https://preprints.jmir.org/preprint/48813

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.